Summary Protein phosphatase 2A (PP2A), one of the main serine–threonine phosphatases
in mammalian cells, maintains cell homoeostasis by counteracting most of the kinase-driven …

The immunomodulatory drug fingolimod (FTY720, Gilenya R) was approved for oral
treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good …

MYC is a master transcriptional regulator that controls almost all cellular processes. Over the
last several decades, researchers have strived to define the context-dependent …

Abstract Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that
regulates many cellular processes. Given the central role of PP2A in regulating diverse …

The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome
including pathways involved in apoptosis, proliferation and DNA damage response and …

FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple
sclerosis that sequesters T-cells to lymph nodes through functional antagonism of …

Abstract Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric enzyme that
catalyzes the selective removal of phosphate groups from protein serine and threonine …

Simple Summary Cancer is the prime cause of death globally. The altered stimulation of
signaling pathways controlled by human kinases has often been observed in various human …

Although various in vitro assays have been developed to evaluate the cytochrome P450
(CYP)-inducing potential of drug candidates, there is a continuing need for the development …